Molecular Staging

Molecular Staging is addressing this demand with a portfolio of products and services based on technologies that are transforming the detection and measurement of both proteins and nucleic acids.

  • brca1Q: What happens that allows mutations in BRCA1 and BRCA2 to lead to cancer rather than causing cell death

    DR. KING: That’s the other big puzzle in this field because these are genes involved in critical pathways. It was clear from very early knockout work that these genes are critical for development. The full knockouts were early embryonic lethals. So why do we ever see tumor development? It’s now clear that p53 may play a role in which alterations of p53 may modify the consequence of the knockout of BRCA1. It may well be the case that there is some small subset of cells, which even if the gene is knocked out, don’t die. Read the rest of this entry »

    No Comments
  • 71085840Q: For twenty years you hammered out the problem of gene-specific causation and were finally able to identify genes associated with breast cancer, BRCA1 and then BRCA2. How are these discoveries affecting breast cancer research?

    DR. KING: I think the discoveries have had two different effects. First and most obviously they have an enormous, direct, clinical, and practical impact on women who carry these mutations. I think there’s no controversy now that BRCA1 and BRCA2 are the major breast cancer genes. Both BRCA1 and BRCA2 have a vast number of different protein-truncating mutations that abrogate their normal functions. But there still remains a great deal of controversy about just what risks for breast cancer and for ovarian cancer are associated with mutations in these genes. Read the rest of this entry »

    No Comments